September 2016
Volume 57, Issue 12
Open Access
ARVO Annual Meeting Abstract  |   September 2016
TWELVE-MONTH FOLLOW-UP OF DEXAMETHASONE IMPLANTS FOR MACULAR EDEMA FROM VARIOUS DISEASES IN VITRECTOMIZED AND NON-VITRECTOMIZED EYES: RESULTS FROM THE PAN AMERICAN COLLABORATIVE RETINA STUDY GROUP
Author Affiliations & Notes
  • Renata Tiemi Kato
    Federal University of Sao Paulo, Sao Paulo, Brazil
  • Eduardo Amorim Novais
    Federal University of Sao Paulo, Sao Paulo, Brazil
  • Mauricio Maia
    Federal University of Sao Paulo, Sao Paulo, Brazil
  • Paulo Augusto de Mello Filho
    Federal University of Sao Paulo, Sao Paulo, Brazil
  • Joao Rafael de Oliveira Dias
    Federal University of Sao Paulo, Sao Paulo, Brazil
  • Marcos Avila
    Federal University of Goiás, Sao Paulo, Brazil
  • Andre Maia
    Federal University of Sao Paulo, Sao Paulo, Brazil
  • J Fernando Arevalo
    Wilmer Eye Institute, John Hopkins University, Maryland, United States
  • Lihteh Wu
    Asociados de Macula, Vitreo y Retina de Costa Rica, San Jose, Costa Rica
  • Maria H Berrocal
    University of Puerto Rico, San Juan, Puerto Rico, United States
  • Michel Farah
    Federal University of Sao Paulo, Sao Paulo, Brazil
  • Footnotes
    Commercial Relationships   Renata Kato, None; Eduardo Novais, None; Mauricio Maia, None; Paulo Mello Filho, Allergan (C); Joao Dias, None; Marcos Avila, None; Andre Maia, None; J Fernando Arevalo, None; Lihteh Wu, None; Maria Berrocal, None; Michel Farah, None
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science September 2016, Vol.57, 4151. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to Subscribers Only
      Sign In or Create an Account ×
    • Get Citation

      Renata Tiemi Kato, Eduardo Amorim Novais, Mauricio Maia, Paulo Augusto de Mello Filho, Joao Rafael de Oliveira Dias, Marcos Avila, Andre Maia, J Fernando Arevalo, Lihteh Wu, Maria H Berrocal, Michel Farah; TWELVE-MONTH FOLLOW-UP OF DEXAMETHASONE IMPLANTS FOR MACULAR EDEMA FROM VARIOUS DISEASES IN VITRECTOMIZED AND NON-VITRECTOMIZED EYES: RESULTS FROM THE PAN AMERICAN COLLABORATIVE RETINA STUDY GROUP. Invest. Ophthalmol. Vis. Sci. 2016;57(12):4151.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : To evaluate the best corrected visual acuity (BCVA), central retinal thickness (CRT), and the number of dexamethasone implants needed to treat cystoid macular edema (CME) from various etiologies over 12 months in vitrectomized and nonvitrectomized eyes.

Methods : This multicenter retrospective cohort study included 112 patients with CME secondary to retinal diseases treated pro re nata (PRN) with a 0.7-mg intravitreal dexamethasone implant for 12 months. The best-corrected VA (BCVA), CRT, intraocular pressure (IOP), need for cataract surgery, safety data, and number of implants were recorded.

Results : Vitrectomized and nonvitrectomized eyes received means of three and one implant, respectively, over 12 months (P<0.001). The mean BCVA of all patients improved from 0.13 at baseline to 0.33 (P<0.001) 12 months after one (P=0.001), two (P=0.041), and three (P<0.001) implants but not four implants (P=0.068). The mean baseline CRT decreased significantly (P<0.001) from 463 to 254 microns after 12 months with one (P<0.001), two (P=0.002), and three (P=0.001) implants but not with four implants (P=0.114). The anatomic and functional outcomes were not significantly different between vitrectomized and nonvitrectomized eyes. Increased IOP was the most common adverse event (23.2%).

Conclusions : The dexamethasone implant administered PRN improved VA and decreased CRT in ME, with possible long-term clinically relevant benefits for treating ME from various etiologies. Vitrectomized eyes needed more implants compared with nonvitrectomized eyes.

This is an abstract that was submitted for the 2016 ARVO Annual Meeting, held in Seattle, Wash., May 1-5, 2016.

 

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×